The aim of this study was to determine the risk of human papillomavirus (HPV)-related carcinomas and premalignancies in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3). Knowledge of this risk is important to preventing the development and progression of other HPVrelated premalignancies and carcinomas, by considering prophylactic HPV vaccination and/or by paying increased attention to other HPV-related carcinomas and premalignancies when CIN3 is identified.
INTRODUCTION
Infections with a high-risk human papillomavirus (hrHPV) are estimated to be the cause of 5.2% of all cancers worldwide. 1 HrHPV infections in women cause cervical cancer and cervical intraepithelial neoplasia (CIN), as well as carcinomas and premalignancies of the oropharynx and anogenital region including the vulva, vagina, and anus.
The prevalence of hrHPV in cervical cancer is close to 100%. In vaginal cancers, the prevalence of hrHPV is 60% to 70%, and in vulvar cancer it ranges from 20% to 50%. In anal cancer, an hrHPV infection is found in 88% to 95% of all cases, and 15% to 65% of oropharyngeal cancers are related to the HPV. 2, 3 It has been shown that women with a diagnosis of CIN grade 3 (CIN3) are at increased risk of carcinomas of the anogenital and head and neck region, probably as the result of an infection with an hrHPV. [4] [5] [6] [7] [8] However, none of those studies included the risk for high-grade premalignancies after a diagnosis of CIN3. 4, 5, [8] [9] [10] Knowledge of this risk is important to preventing the development and progression of other HPV-related premalignancies and carcinomas, by considering prophylactic HPV vaccination and/or by paying increased attention to other HPV-related carcinomas and premalignancies when CIN3 identified. Primary prevention of HPV-related carcinomas and premalignancies by prophylactic vaccination is now only available for young women. Older and unvaccinated women are therefore still at risk for HPV-related disease in the next decades. Treating premalignancies in a cohort may prevent malignancies from developing, and the risk for HPVrelated carcinomas and premalignancies combined represents the possible preventive effect of HPV vaccination in women with a CIN3. The aim of this study was therefore to determine the risk of HPV-related carcinomas and premalignancies in women with a previous histologic diagnosis of CIN3.
METHODS
Women with a diagnosis of CIN3 between January 1, 1990, and December 31, 2010, were identified from the Dutch nationwide registry of histopathology and cytopathology (PALGA; Houten, Netherlands). Date of birth and first four letters of the surname were used as a personal identifier. Women registered in the database with a benign dermal nevus, but who were never diagnosed with CIN3 or cervical carcinoma before or after the diagnosis of nevus, were selected from the database as a control group. Registration of a pathology result in the database was needed to obtain a control group from the database; a registered benign dermal nevus was chosen because it is not related to HPV and can be diagnosed in all women. Women with both a CIN3 and a benign nevus diagnosis were included in the CIN3 group. Control subjects were assigned a random number and sorted. Subsequently, from the total group of 547,924 matched women with a nevus, random frequency matching was done by age and year of detection (both within a range of 5 years), and population density areas; smaller cities with , 100,000 inhabitants were considered low-density areas, and those with . 100,000 inhabitants were considered higherdensity cities. For all identified women, histology results for carcinomas and high-grade premalignancies of the vulva, vagina, perineum, anus, and oropharynx between January 1, 1990, and March 1, 2015, were retrieved, resulting in 4 to 25 years of follow-up. In addition, patient age and date of diagnosis were retrieved.
We identified all HPV-related carcinomas and premalignancies diagnosed after the CIN3 or benign dermal nevus. Only results with a clear diagnosis of malignancy were classified as cancer; when invasiveness was uncertain in a high-grade lesion, the result was classified as a high-grade premalignancy. Moderate (CIN2) and low-grade (CIN1) premalignancies were not included in the high-grade group. Women were censored after diagnosis of an HPV-related carcinoma of any site because treatment might influence the subsequent risk of other carcinomas or premalignancies. Women with an HPV-related carcinoma or premalignancy before the CIN3 or benign dermal nevus were excluded from analysis, as well as results indicating recurrence or metastases of disease. Differentiated vulvar intraepithelial neoplasia (VIN) and vulvar cancer after a previous diagnosis of lichen sclerosis, clear cell carcinomas, serous adenocarcinoma, lymphomas, melanomas, and basal cell carcinomas were also excluded because these are not likely to be related to HPV. 11, 12 We calculated person-years at risk and the number of observed carcinomas and premalignancies in each group, taking into account censoring as described in the previous paragraph. Using Poisson regression with an offset on the basis of the person-years, incidence rates (IR) per 100,000 person-years were estimated for both cases and their matched controls. Incidence rate ratios (IRR), comparing women with a CIN3 diagnosis with the matched control group, were computed, first by analyzing the whole follow-up period and second by excluding the first year of follow-up, to account for possibly prevalent HPVrelated carcinomas and premalignancies in the cohort. HPV-related carcinomas and premalignancies were analyzed separately and combined into clusters of any HPV-related carcinoma and/or any HPVrelated premalignancy. The cluster of any HPV-related carcinoma includes anal cancer, vulvar cancer, vaginal cancer, and oropharyngeal cancer. The cluster of any HPV-related premalignancy includes anal intraepithelial neoplasia grade 3 (AIN3), VIN grade 3 (VIN3), and vaginal intraepithelial neoplasia grade 3 (VAIN3). The cluster of any malignancy or premalignancy includes anal cancer, AIN3, vulvar cancer, VIN3, vaginal cancer, VAIN3, and oropharyngeal cancer. In all analyses, person-years were only considered before the first diagnosed carcinoma or premalignancy.
Age-adjusted IRRs for 5-year follow-up intervals were estimated for up to 25 years of follow-up for each carcinoma and premalignancy separately and for the clustered carcinomas and premalignancies, by means of a Poisson model with an interaction term for the group with a history of CIN3 and follow-up period and a continuous variable for age. In addition, IRRs were estimated for women # 29 years, 30 to 49 years, 50 to 69 years, and $ 70 years of age for the clustered carcinomas and premalignancies. Kaplan-Meier curves were used to visualize the risk of HPV-related carcinomas and premalignancies over time.
All statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC). Kaplan-Meier curves were obtained with SPSS version 22.0.0.1 for Windows (SPSS, Chicago, IL).
The study was approved by the scientific committee of PALGA. The study was exempt from institutional review board approval because data were gathered retrospectively and analyzed anonymously.
RESULTS
We identified 178,036 women, of whom 89,018 had a histologic diagnosis of CIN3, between 1990 and 2010, and an equal number of women in the matched control group of women without a history of CIN3. The median age at diagnosis was 35 years in women with a previous diagnosis of CIN3, and 36 years in the control group. Characteristics of the study population at inclusion are listed in Table 1 . During a median follow-up of 14 years in both groups (range, 4 to 25 years), 1,261,804 person-years were accrued in the group with a previous diagnosis of CIN3. After censoring, a total of 299 HPV-related carcinomas and 634 HPV-related premalignancies were found in the group with a previous diagnosis of CIN3. In the control group, 1,262,998 person-years were accrued, with 48 HPV-related carcinomas and 50 HPV-related premalignancies ( Table 2) .
The risk of developing HPV-related carcinomas and premalignancies of the anus, vulva, vagina, and oropharynx is strongly associated with a previous diagnosis of CIN3, with a significant increase in the group with a history of CIN3 (Fig 1) . The IRRs for anal cancer and AIN3, comparing women with a previous diagnosis of CIN3 with those without a previous diagnosis of CIN3, were 3.85 (95% CI, 2.32 to 6.37) and 6.68 (95% CI, 3.64 to 12.25), respectively. For vulvar cancer and VIN3, the IRRs were 4.97 (95% CI, 3.26 to 7.57) and 13.66 (95% CI, 9.69 to 19.25), respectively. Vaginal cancer and VAIN3 showed the highest IRRs, with 86.08 jco.org (95% CI, 11.99 to 618.08) for vaginal cancer and 25.65 (95% CI, 10.50 to 62.69) for VAIN3, as the result of low IRs in the control group. Oropharyngeal cancer showed an IRR of 5.51 (95% CI, 1.22 to 24.84). The IRR for any HPV-related carcinoma was 6.24 (95% CI, 4.60 to 8.46), for any HPV-related premalignancy the IRR was 12.75 (95% CI, 9.56 to 17.00), and for any HPV-related carcinoma or premalignancy the IRR was 9.68 (95% CI, 7.77 to 12.05). Excluding the first year after inclusion resulted in IRR estimates that were not notably different ( Table 2) .
The age-adjusted IRR stratified by time interval since first diagnosis showed a short-term and a long-lasting increased risk of developing HPV-related carcinomas and premalignancies in women with a previous diagnosis of CIN3, when compared with the control group of women without a CIN3 diagnosis. Even up to 20 years after the CIN3 diagnosis, this risk remained increased ( Table 3 ). The increased cumulative incidence over time is clearly visualized in the Kaplan-Meier curves (Fig 2) . For the cluster of any HPV-related carcinoma or premalignancy, the IRR decreased over time; however, an increased risk was still visible after long-term follow-up ( Fig 3) .
IRR stratified by attained age showed that the risk of carcinoma or premalignancies for women with a history of CIN3 might be dependent on age. The IRR of any HPV-related premalignancy and of any carcinoma or premalignancy was highest in women # 29 years of age, both with an IRR . 30. The IRR for women with any HPV-related carcinoma was not available. In the group of women between 30 and 49 years of age, the risk was lower compared with women # 29 years of age; however, the risk was higher compared with older age groups, with IRRs of 8.09 (95% CI, 4.81 to 13.58) for any HPV-related carcinoma, 16.68 (95% CI, 11.14 to 24.96) for any HPV-related premalignancy, and 13.62 (95% CI, 9.76 to 19.01) for any HPV-related carcinoma or premalignancy (Appendix Table A1 , online only).
DISCUSSION
This population-based cohort study, which included 178,036 women, showed an increased risk of premalignancies as well as carcinomas of the anus, vulva, vagina, and oropharynx in women with a previous diagnosis of CIN3 compared with women without a previous diagnosis of CIN3. The increased risk was still present up to 20 years after the CIN3 diagnosis.
Our results are consistent with published studies on HPVrelated carcinomas in women with a CIN diagnosis, with risk ratios ranging from 2.2 to 4.4 for vulvar cancer, 6.7 to 18.5 for vaginal cancer, 1.8 to 5.9 for anal cancer, and 1.2 for oral/pharyngeal tumors. 4, 5, [7] [8] [9] No studies have analyzed the risk of HPV-related high-grade premalignancies. In general, high-grade premalignancies are treated before cancer can occur. Our data on IRs of high-grade premalignancies showed high IRRs, indicating that in the group of women with CIN3, carcinomas may have been prevented by early detection and treatment of high-grade premalignancies. Our data overall showed higher IRRs compared with published results. This might be caused by differences in our study design compared with published studies. Some studies used expected IRs on the basis of national averaged IRs, which may also include carcinomas in women with a CIN3 in the control group, whereas others used relative risks. Furthermore, the studies by Kalliala et al 4 and Gaudet et al 8 included women with CIN1 and/or CIN2, of which CIN1 is known to show a lower prevalence of hrHPV compared with CIN2/3. 13 
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Our results showed the highest IRRs for vaginal cancer and VAIN3 and the lowest IRR for anal cancer, which was still 3.85 (95% CI, 2.32 to 6.37). Vaginal abnormalities are in proximity to cervical abnormalities; this makes a vaginal coinfection, with development of a vaginal carcinoma or premalignancy, more likely in women with a CIN3. This risk is much lower in women with no history of CIN3, which was shown by a low IR in the control group, resulting in a high IRR in vaginal cancer and VAIN3 after a CIN3. Also, in vulvar carcinomas and premalignancies, a loco-regional effect of HPV may explain an increased incidence of these lesions in women diagnosed with a CIN3. Women diagnosed with a CIN3 are commonly followed up with cervical smears or colposcopic examination. This may also result in increased detection of premalignancies of the vagina and vulva, with a higher IR in women with a CIN3 compared with women without a CIN3; this could result in an overestimation of IRR, especially in these two premalignancies. Also, not all anal, vulvar, vaginal, and oropharyngeal carcinomas and premalignancies are related to HPV; therefore, not all malignancies and premalignancies detected during follow-up in this study are related to HPV. We attempted to exclude carcinomas and premalignancies that were definitely not related to HPV. However, in the majority of cases, HPV tests were not performed on the histology samples; thus, some carcinomas and premalignancies not caused by HPV still would have been included. However, these carcinomas and premalignancies have been included in both the CIN3 group and in the control group of women without CIN3, with an expected similar number of cases; therefore, in estimated IRRs, these numbers cancel each other out. The overall increased IRR might also be explained by a woman's inability or limited ability to clear an hrHPV infection. A limited ability or inability to clear hrHPV infections did result in a persistent hrHPV infection with development of a CIN3 lesion, but could have also resulted in other HPV-related carcinomas and premalignancies. The long-lasting increased risk might also be explained by increased susceptibility to new hrHPV infections and recrudescence of disease because of an inability to clear the infection. It is known that smoking and immunodeficiency increases the risk of persistent hrHPV Estimated incidence rates of human papillomavirus (HPV)-related carcinomas and premalignancies, comparing women with and without a history of cervical intraepithelial neoplasia grade 3 (CIN3). The first year after diagnosis of CIN3 or benign dermal nevus was included in the incidence rate visualized in this figure. Error bars indicate 95% CIs of estimated incidence rates. The asterisks indicate a significant difference in incidence rates of the group with a history of CIN3 compared with the group without a history of CIN3. Data are in Table 2 . AIN3, anal intraepithelial neoplasia grade 3; VAIN3, vaginal intraepithelial neoplasia grade 3; VIN3, vulvar intraepithelial neoplasia grade 3. infections, with an increased risk of (pre)malignant development. [14] [15] [16] Data on smoking or immune status were not registered in the PALGA database, and could therefore not be included in our analysis. Published results, however, show no increased risk explained by smoking. 9 When looking at IRR over time, almost all IRRs showed a steady decline of increased risk during the long-term follow-up, with the lowest increased risk after 20 to 24 years. The Kaplan-Meier curves of all HPV-related carcinomas and premalignancies also confirmed this long-term increased risk. The increased risk of the cluster of any HPV-related carcinoma or premalignancy over time showed a decrease over time with an IRR of 16.44 (95% CI, 8.68 to 31.13) in the first year, and an IRR of 2.57 (95% CI, 1.38 to 5.18) after 20 years. This indicates that although the risk of HPVrelated carcinomas and premalignancies decreased over time, it was still significantly increased up to 20 years after the CIN3 diagnosis. A previous study by Gaudet et al 8 also showed dropping incidences of malignancies over time, but to the contrary, Kalliala et al 4 showed an increased standardized IR for malignancies over time after CIN3 treatment. For clusters of all carcinomas and/or all premalignancies, we also observed decreasing IRRs with advancing age. These data should be interpreted with some caution because the effect of a low incidence of malignancies in younger age groups might also be a confounding factor.
Ideally, we want to prevent the development of HPV-related carcinomas or high-grade premalignancies, or at least discover premalignancies before they progress to cancer. Higher alertness 
20-24 Years
Incidence Rate Ratio Table 3 .
for HPV-related lesions in women with CIN3 might therefore be advisable. During colposcopy, it is relatively easy to look for vaginal carcinoma and premalignancies. Current guidelines advise to also examine the vaginal walls during colposcopic examination, and when an abnormal smear is not explained by cervical abnormalities, a vaginoscopy can be considered. When VAIN is diagnosed, it can be treated with surgical excision, laser evaporation, or imiquimod; however, recurrent disease is a known problem. 17 Also, screening for vulvar and anal carcinoma and premalignancies might be easily combined with cervical diagnostics. Visual inspection will be easy to implement, but presently data are lacking that screening of these areas results in a lower cancer incidence. Indeed, there are no current screening programs for VIN, AIN, or oropharyngeal lesions, but if premalignancies are encountered, they are treated. 18, 19 Because an infection with hrHPV is causal to the development of other HPV-related carcinomas and high-grade premalignancies, prophylactic HPV vaccination may have a preventive effect on development of these lesions. However, the role of prophylactic vaccination in adult women is debated. Previous vaccination trials have shown that noninfected adults could potentially benefit from HPV vaccination. 20, 21 Garland et al 22 showed that women undergoing surgical therapy for cervical lesions after vaccination with the bivalent vaccine may benefit from vaccination, with a reduced risk of developing subsequent CIN2 positivity. Studies in women with a current infection with hrHPV showed varying results. Two recent studies showed a reduced incidence of subsequent HPVrelated disease in women vaccinated with the quadrivalent HPV vaccine after surgical treatment of CIN3 when compared with surgically treated women who did not receive the HPV vaccination. 23, 24 On the contrary, a recent study by Hildesheim et al 25 showed no evidence for a vaccine effect on detectable HPV infections in hrHPV-positive women and women undergoing treatment of cervical premalignancy. Also, the small potential harms of vaccination should be taken into account, alongside the fact that HPV infections leading to premalignancies or malignancies may have been acquired before the HPV vaccination. It is therefore not fully clarified how clinically and cost effective prophylactic hrHPV vaccination would be in women treated for CIN3. Randomized controlled trials and cost-effectiveness studies might answer these questions. Our study, however, showed that shortand long-term risks of HPV-related abnormalities are strongly increased in women diagnosed with CIN3. Patients should be informed on an individual basis about this increased risk. The Dutch guideline presently advises to consider hrHPV vaccination in women diagnosed with CIN3, until more conclusive evidence on vaccine effect after treatment of CIN3 is available. 17 The introduction of prophylactic HPV vaccination is expected to reduce the incidence of HPV-related cancers; postvaccination surveillance studies have supported this by showing a significant reduction of 68% in type 16 and 18 infections in countries with female vaccination coverage of $ 50%. [26] [27] [28] [29] However, monitoring remains essential to identify possible waning of efficacy or replacement of HPV type. Because vaccination programs for young women only started in 2007, it will take many more years before the effects of HPV vaccination become visible in the total adult female population.
In conclusion, this population-based data set shows further evidence of the increased risk of HPV-related carcinomas and premalignancies of the anogenital and oropharyngeal regions after a diagnosis of CIN3, and gives a clear view of women at risk for HPV-related disease. Studies that investigate methods to prevent this increased risk in this group of patients, such as intensified screening or vaccination, are warranted.
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